Bipolar Disorder (2018) |
1.67 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PPP1R13B |
Bipolar Disorder or Schizophrenia |
2.70 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 PPP1R13B |
Depressed Affect (Nagel 2018) |
2.40 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
AATK CTTNBP2 PHF5A |
Depression (Nagel 2018) |
2.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK |
Intelligence (Savage-Jansen 2018) |
1.19 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK PPP1R13B |
Neuroticism (Nagel 2018) |
3.97 |
5 |
1 |
2.2 |
-0.34 |
5.8e-01 |
AATK C10orf32 CTTNBP2 PHF5A PRPS1P2 |
Schizophrenia (2018) |
2.83 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 CLU PPP1R13B |
Schizophrenia vs Biploar Disorder |
1.58 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CLU |
Worry (Nagel 2018) |
4.08 |
4 |
2 |
4.4 |
-0.18 |
8.2e-01 |
AATK C10orf32 NT5C2 PRPS1P2 |
Alzheimer’s Disease (including proxy) |
1.73 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CLU |
Crohns Disease (2017) |
3.07 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHF5A RTEL1 |
Irritable Bowel Disease (IBD) |
3.18 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RTEL1 |
Ulcerative Colitis (UC) |
2.24 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RTEL1 |
Major Depression (MDD) |
3.49 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTTNBP2 |
Verbal and Numeric Reasoning (VNR) |
1.33 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PPP1R13B |
Breast Cancer |
0.85 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CLU |
Prostate Cancer |
4.60 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RTEL1 |
Coronary Artery Disease (CAD) |
1.53 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 |
Crohns Disease (2012) |
2.97 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RTEL1 |
Neuroticism (2016) |
2.59 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK |
Schizophrenia (2014) |
2.68 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 CLU PPP1R13B |
Ulcerative Colitis |
2.25 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RTEL1 |
Blood Eosinophil Count |
1.45 |
4 |
1 |
2.2 |
0.24 |
7.6e-01 |
AATK PHF5A PPP1R13B SURF1 |
Blood Platelet Count |
0.99 |
4 |
2 |
4.4 |
0.96 |
3.9e-02 |
C10orf32 NT5C2 PHF5A RTEL1 |
Blood Red Count |
0.94 |
4 |
2 |
4.4 |
0.99 |
9.6e-03 |
MAPKAP1 PPP1R13B RTEL1 SURF1 |
Blood White Count |
2.17 |
7 |
4 |
8.9 |
0.99 |
4.7e-05 |
AATK C10orf32 NT5C2 PPP1R13B RTEL1 SEMA6D SURF1 |
Heel T-Score |
1.17 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHF5A PPP1R13B RTEL1 |
BMI |
1.72 |
5 |
1 |
2.2 |
0.73 |
1.6e-01 |
C10orf32 MAPKAP1 PPP1R13B RAB4B RP11-122A3.2 |
Height |
1.82 |
12 |
7 |
15.6 |
-0.36 |
2.6e-01 |
AATK C10orf32 CLU COQ5 CTTNBP2 MAPKAP1 NT5C2 PHF5A PPP1R13B PRPS1P2 RP11-122A3.2 RTEL1 |
Waist Hip Ratio (WHR) |
1.46 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 PRPS1P2 SEMA6D |
Systolic Blood Pressure |
2.24 |
5 |
2 |
4.4 |
-0.69 |
2.0e-01 |
C10orf32 COQ5 MAPKAP1 RP11-122A3.2 RTEL1 |
Smoking Status |
18.02 |
14 |
9 |
20.0 |
0.96 |
3.5e-08 |
AATK C10orf32 CLU COQ5 CTTNBP2 MAPKAP1 NT5C2 PHF5A PPP1R13B PRPS1P2 RP11-122A3.2 RTEL1 SEMA6D SURF1 |
Allergy or Eczema |
2.91 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
NT5C2 PHF5A RTEL1 |
Cardiovascular Disease |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
Hypothyroidism (self reported) |
1.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHF5A |
Respiratory disease |
2.65 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHF5A RTEL1 |
Type 2 Diabetes (T2D) (2018) |
2.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RTEL1 |
Lung FEV1/FVC ratio |
1.18 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 CTTNBP2 RAB4B |
Lung FVC |
2.46 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CTTNBP2 PRPS1P2 RTEL1 |
Neuroticism |
3.66 |
5 |
1 |
2.2 |
-0.22 |
7.2e-01 |
AATK C10orf32 CTTNBP2 PHF5A PRPS1P2 |
Chronotype (morning person) |
1.40 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHF5A |
Hair Pigment |
0.23 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHF5A PPP1R13B RTEL1 |
Tanning |
0.33 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 MAPKAP1 |
Hand grip strength (left) |
2.41 |
4 |
0 |
0.0 |
-0.07 |
9.3e-01 |
C10orf32 MAPKAP1 NT5C2 PRPS1P2 |
Sensitivity / hurt feelings |
3.43 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK MAPKAP1 PRPS1P2 |
Frequency of depressed mood in last 2 weeks |
2.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK |
Systolic blood pressure, automated reading |
2.02 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 MAPKAP1 RTEL1 |
Medication for hormone replacement therapy |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RAB4B |
Vitamin and mineral supplements |
1.64 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NT5C2 |
Diabetes (mother) |
2.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
COQ5 |
Pack years adult smoking proportion |
6.26 |
5 |
1 |
2.2 |
0.47 |
4.3e-01 |
MAPKAP1 PPP1R13B RAB4B SEMA6D SURF1 |
Impedance of leg (right) |
1.36 |
5 |
0 |
0.0 |
0.48 |
4.1e-01 |
C10orf32 PPP1R13B PRPS1P2 RTEL1 SEMA6D |
Leg fat-free mass (left) |
1.49 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 PRPS1P2 |
Trunk fat percentage |
1.75 |
4 |
1 |
2.2 |
-0.12 |
8.8e-01 |
PHF5A RP11-122A3.2 RTEL1 SEMA6D |
Hand grip strength (right) |
2.50 |
4 |
1 |
2.2 |
-0.16 |
8.4e-01 |
C10orf32 MAPKAP1 NT5C2 PRPS1P2 |
Townsend deprivation index at recruitment |
4.06 |
4 |
0 |
0.0 |
0.98 |
1.7e-02 |
C10orf32 CTTNBP2 MAPKAP1 PRPS1P2 |
Maternal smoking around birth |
6.30 |
4 |
0 |
0.0 |
0.99 |
1.3e-02 |
C10orf32 NT5C2 PHF5A PPP1R13B |
Fed-up feelings |
2.26 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK CTTNBP2 PHF5A |
Frequency of unenthusiasm / disinterest in last 2 weeks |
3.13 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK CTTNBP2 |
Age when periods started (menarche) |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 |
High blood pressure |
0.96 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
Hayfever, allergic rhinitis or eczema |
2.75 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
NT5C2 PHF5A RTEL1 |
Sitting height |
1.19 |
6 |
0 |
0.0 |
-0.39 |
4.4e-01 |
AATK C10orf32 MAPKAP1 PRPS1P2 RP11-122A3.2 SURF1 |
Body mass index (BMI) |
1.63 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 PPP1R13B RP11-122A3.2 |
Impedance of leg (left) |
1.36 |
4 |
0 |
0.0 |
0.63 |
3.7e-01 |
PPP1R13B PRPS1P2 RTEL1 SEMA6D |
Leg predicted mass (left) |
1.48 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 PRPS1P2 |
Trunk fat mass |
1.68 |
4 |
0 |
0.0 |
-0.34 |
6.6e-01 |
C10orf32 PHF5A RTEL1 SEMA6D |
Waist circumference |
1.94 |
4 |
0 |
0.0 |
0.99 |
7.8e-03 |
C10orf32 PPP1R13B RP11-122A3.2 RTEL1 |
Number of incorrect matches in round |
2.61 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 |
Past tobacco smoking |
8.37 |
6 |
3 |
6.7 |
-0.76 |
7.8e-02 |
C10orf32 CLU CTTNBP2 NT5C2 PRPS1P2 RAB4B |
Alcohol usually taken with meals |
4.07 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CLU CTTNBP2 NT5C2 |
Nervous feelings |
3.31 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
AATK C10orf32 PRPS1P2 |
Frequency of tenseness / restlessness in last 2 weeks |
2.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK |
Forced vital capacity (FVC) |
2.03 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
PRPS1P2 RTEL1 |
Qualifications: None of the above |
2.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SEMA6D |
Financial difficulties in last 2 years |
3.33 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PPP1R13B |
Mouth/teeth dental problems |
3.28 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK PRPS1P2 |
Allergy |
3.07 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
PHF5A RTEL1 |
Fluid intelligence score |
1.56 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK PPP1R13B |
Neuroticism score |
3.32 |
4 |
1 |
2.2 |
-0.55 |
4.5e-01 |
AATK CTTNBP2 PHF5A PRPS1P2 |
Weight |
1.61 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PHF5A |
Impedance of arm (right) |
1.39 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 PHF5A RAB4B |
Arm fat percentage (right) |
1.97 |
5 |
0 |
0.0 |
0.13 |
8.4e-01 |
MAPKAP1 PHF5A PPP1R13B RP11-122A3.2 SEMA6D |
Trunk fat-free mass |
1.52 |
4 |
2 |
4.4 |
0.06 |
9.4e-01 |
C10orf32 MAPKAP1 NT5C2 PRPS1P2 |
Hip circumference |
1.86 |
4 |
1 |
2.2 |
0.23 |
7.7e-01 |
C10orf32 PPP1R13B RTEL1 SEMA6D |
Alcohol intake versus 10 years previously |
3.66 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CLU CTTNBP2 NT5C2 |
Father's age at death |
2.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CLU |
Worrier / anxious feelings |
4.09 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PHF5A |
Frequency of tiredness / lethargy in last 2 weeks |
3.32 |
4 |
0 |
0.0 |
-0.51 |
4.9e-01 |
AATK PHF5A PPP1R13B PRPS1P2 |
Forced expiratory volume in 1-second (FEV1) |
2.24 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
CTTNBP2 PRPS1P2 RTEL1 |
Pulse rate |
2.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
Qualifications: A levels/AS levels or equivalent |
2.04 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTTNBP2 SEMA6D |
Mouth/teeth dental problems: Dentures |
2.86 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CLU |
Asthma |
1.74 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHF5A RTEL1 |
Lung cancer (father) |
2.68 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CLU |
Forced expiratory volume in 1-second (FEV1), Best measure |
1.61 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 RTEL1 |
Pulse wave Arterial Stiffness index |
1.87 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 |
Impedance of arm (left) |
1.49 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 PHF5A |
Arm fat mass (right) |
1.71 |
5 |
0 |
0.0 |
0.13 |
8.3e-01 |
C10orf32 PHF5A PPP1R13B RP11-122A3.2 SEMA6D |
Trunk predicted mass |
1.53 |
4 |
2 |
4.4 |
0.06 |
9.4e-01 |
C10orf32 MAPKAP1 NT5C2 PRPS1P2 |
Standing height |
1.59 |
7 |
3 |
6.7 |
-0.70 |
7.7e-02 |
AATK C10orf32 COQ5 MAPKAP1 PHF5A PRPS1P2 RP11-122A3.2 |
Tense / 'highly strung' |
2.60 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK PHF5A |
Seen doctor (GP) for nerves, anxiety, tension or depression |
3.01 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK CTTNBP2 PRPS1P2 |
Birth weight of first child |
1.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 |
Peak expiratory flow (PEF) |
2.50 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 CTTNBP2 PRPS1P2 |
Medication for cholesterol, blood pressure or diabetes |
0.84 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
Medication: Amlodipine |
1.84 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
Medication: Ventolin 100micrograms inhaler |
2.40 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHF5A |
Birth weight |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 |
Forced vital capacity (FVC), Best measure |
1.48 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PRPS1P2 RTEL1 |
Body fat percentage |
1.87 |
4 |
0 |
0.0 |
0.52 |
4.8e-01 |
MAPKAP1 PHF5A RP11-122A3.2 RTEL1 |
Leg fat percentage (right) |
1.96 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 RP11-122A3.2 RTEL1 |
Arm fat-free mass (right) |
1.52 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PRPS1P2 |
Exposure to tobacco smoke outside home |
4.38 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 CTTNBP2 |
Comparative body size at age 10 |
1.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHF5A |
Worry too long after embarrassment |
2.14 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTTNBP2 PRPS1P2 |
Seen a psychiatrist for nerves, anxiety, tension or depression |
2.75 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTTNBP2 PRPS1P2 |
Wheeze or whistling in the chest in last year |
2.89 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RTEL1 |
Pulse wave peak to peak time |
1.94 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 |
Qualifications: College or University degree |
2.89 |
6 |
1 |
2.2 |
-0.99 |
3.2e-04 |
C10orf32 CTTNBP2 NT5C2 PRPS1P2 RTEL1 SEMA6D |
Medication for pain relief, constipation, heartburn |
2.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 |
Medication: Blood pressure |
0.82 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
Medication: Allopurinol |
1.53 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RAB4B |
Whole body fat mass |
1.84 |
5 |
0 |
0.0 |
0.17 |
7.8e-01 |
C10orf32 PHF5A RP11-122A3.2 RTEL1 SEMA6D |
Leg fat mass (right) |
1.85 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 RP11-122A3.2 RTEL1 |
Arm predicted mass (right) |
1.56 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PRPS1P2 |
Pulse rate, automated reading |
3.48 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
MAPKAP1 RP11-122A3.2 RTEL1 |
Alcohol intake frequency. |
1.83 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHF5A |
Comparative height size at age 10 |
1.17 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 COQ5 MAPKAP1 |
Suffer from 'nerves' |
2.43 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK C10orf32 |
Overall health rating |
3.06 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK MAPKAP1 PRPS1P2 |
Commuting to job workplace: Car/motor vehicle |
1.74 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP11-122A3.2 |
Illness, injury, bereavement, stress in last 2 years |
2.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTTNBP2 |
Hypertension (Self-reported) |
0.94 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
Smoking status: Previous |
4.60 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 RAB4B |
Forced expiratory volume in 1-second (FEV1), predicted |
1.50 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 |
Whole body fat-free mass |
1.48 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PRPS1P2 |
Leg fat-free mass (right) |
1.51 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 PRPS1P2 |
Arm fat percentage (left) |
1.92 |
5 |
0 |
0.0 |
0.07 |
9.1e-01 |
MAPKAP1 PHF5A PPP1R13B RP11-122A3.2 SEMA6D |
Mood swings |
2.55 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTTNBP2 PHF5A |
Long-standing illness, disability or infirmity |
2.56 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CLU |
Ever had bowel cancer screening |
2.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SURF1 |
Asthma (self-reported) |
1.81 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PHF5A RTEL1 |
Osteoarthritis (self-reported) |
2.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
Smoking status: Current |
17.76 |
15 |
9 |
20.0 |
1.00 |
3.8e-17 |
AATK C10orf32 CLU COQ5 CTTNBP2 MAPKAP1 NT5C2 PHF5A PPP1R13B PRPS1P2 RAB4B RP11-122A3.2 RTEL1 SEMA6D SURF1 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
2.02 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PRPS1P2 RTEL1 |
Whole body water mass |
1.47 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PRPS1P2 |
Leg predicted mass (right) |
1.49 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 PRPS1P2 |
Arm fat mass (left) |
1.70 |
5 |
0 |
0.0 |
0.11 |
8.5e-01 |
C10orf32 PHF5A PPP1R13B RP11-122A3.2 SEMA6D |
Number of self-reported non-cancer illnesses |
2.56 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHF5A RTEL1 |
Miserableness |
1.84 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK CTTNBP2 |
Guilty feelings |
2.40 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AATK |
Mother's age at death |
2.64 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 |
High cholesterol (Self-reported) |
1.33 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SURF1 |
Ever smoked |
8.38 |
5 |
4 |
8.9 |
0.98 |
3.9e-03 |
AATK C10orf32 CTTNBP2 NT5C2 PRPS1P2 |
Basal metabolic rate |
1.45 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PRPS1P2 |
Leg fat percentage (left) |
2.17 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
MAPKAP1 RP11-122A3.2 RTEL1 |
Arm fat-free mass (left) |
1.49 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PRPS1P2 |
Irritability |
2.59 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHF5A |
Risk taking |
3.08 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NT5C2 PPP1R13B |
Fractured/broken bones in last 5 years |
1.83 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTTNBP2 |
Diastolic blood pressure, automated reading |
2.21 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
MAPKAP1 NT5C2 RTEL1 |
Vascular/heart problems diagnosed by doctor |
1.09 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAPKAP1 NT5C2 |
Pain experienced in last month |
1.79 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 |
Basal cell carcinoma (self-reported) |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PHF5A |
Pack years of smoking |
6.06 |
4 |
1 |
2.2 |
0.41 |
5.9e-01 |
PPP1R13B RAB4B SEMA6D SURF1 |
Impedance of whole body |
1.42 |
4 |
1 |
2.2 |
0.55 |
4.5e-01 |
C10orf32 PHF5A PPP1R13B PRPS1P2 |
Leg fat mass (left) |
1.95 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 RP11-122A3.2 RTEL1 |
Arm predicted mass (left) |
1.47 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 NT5C2 PRPS1P2 |